A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction

Barbara P. Yawn, Patricia Saddier, Peter C. Wollan, Jennifer St. Sauver, Marge J. Kurland, Lina S. Sy

Research output: Contribution to journalArticle

522 Citations (Scopus)

Abstract

OBJECTIVE: To establish accurate, up-to-date, baseline epidemiological data for herpes zoster (HZ) before the introduction of the recently licensed HZ vaccine. METHODS: Using data from January 1, 1996, to October 15, 2005, we conducted a population-based study of adult residents (≥22 years) of Olmsted County, MN, to determine (by medical record review) the incidence of HZ and the rate of HZ-related complications. Incidence rates were determined by age and sex and adjusted to the US population. RESULTS: A total of 1669 adult residents with a confirmed diagnosis of HZ were identified between January 1, 1996, and December 31, 2001. Most (92%) of these patients were immunocompetent and 60% were women. When adjusted to the US adult population, the incidence of HZ was 3.6 per 1000 person-years (95% confidence interval, 3.4-3.7), with a temporal increase from 3.2 to 4.1 per 1000 person-years from 1996 to 2001. The incidence of HZ and the rate of HZ-associated complications increased with age, with 68% of cases occurring in those aged 50 years and older. Postherpetic neuralgia occurred in 18% of adult patients with HZ and in 33% of those aged 79 years and older. Overall, 10% of all patients with HZ experienced 1 or more nonpain complications. CONCLUSIONS: Our population-based data suggest that HZ primarily affects immunocompetent adults older than 50 years; 1 in 4 experiences some type of HZ-related complication.

Original languageEnglish (US)
Pages (from-to)1341-1349
Number of pages9
JournalMayo Clinic Proceedings
Volume82
Issue number11
DOIs
StatePublished - 2007

Fingerprint

Herpes Zoster Vaccine
Herpes Zoster
Cohort Studies
Population
Incidence
Postherpetic Neuralgia
Medical Records

ASJC Scopus subject areas

  • Medicine(all)

Cite this

A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. / Yawn, Barbara P.; Saddier, Patricia; Wollan, Peter C.; St. Sauver, Jennifer; Kurland, Marge J.; Sy, Lina S.

In: Mayo Clinic Proceedings, Vol. 82, No. 11, 2007, p. 1341-1349.

Research output: Contribution to journalArticle

Yawn, Barbara P. ; Saddier, Patricia ; Wollan, Peter C. ; St. Sauver, Jennifer ; Kurland, Marge J. ; Sy, Lina S. / A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. In: Mayo Clinic Proceedings. 2007 ; Vol. 82, No. 11. pp. 1341-1349.
@article{16c331e8a7304d3da3d25365b6627254,
title = "A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction",
abstract = "OBJECTIVE: To establish accurate, up-to-date, baseline epidemiological data for herpes zoster (HZ) before the introduction of the recently licensed HZ vaccine. METHODS: Using data from January 1, 1996, to October 15, 2005, we conducted a population-based study of adult residents (≥22 years) of Olmsted County, MN, to determine (by medical record review) the incidence of HZ and the rate of HZ-related complications. Incidence rates were determined by age and sex and adjusted to the US population. RESULTS: A total of 1669 adult residents with a confirmed diagnosis of HZ were identified between January 1, 1996, and December 31, 2001. Most (92{\%}) of these patients were immunocompetent and 60{\%} were women. When adjusted to the US adult population, the incidence of HZ was 3.6 per 1000 person-years (95{\%} confidence interval, 3.4-3.7), with a temporal increase from 3.2 to 4.1 per 1000 person-years from 1996 to 2001. The incidence of HZ and the rate of HZ-associated complications increased with age, with 68{\%} of cases occurring in those aged 50 years and older. Postherpetic neuralgia occurred in 18{\%} of adult patients with HZ and in 33{\%} of those aged 79 years and older. Overall, 10{\%} of all patients with HZ experienced 1 or more nonpain complications. CONCLUSIONS: Our population-based data suggest that HZ primarily affects immunocompetent adults older than 50 years; 1 in 4 experiences some type of HZ-related complication.",
author = "Yawn, {Barbara P.} and Patricia Saddier and Wollan, {Peter C.} and {St. Sauver}, Jennifer and Kurland, {Marge J.} and Sy, {Lina S.}",
year = "2007",
doi = "10.4065/82.11.1341",
language = "English (US)",
volume = "82",
pages = "1341--1349",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "11",

}

TY - JOUR

T1 - A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction

AU - Yawn, Barbara P.

AU - Saddier, Patricia

AU - Wollan, Peter C.

AU - St. Sauver, Jennifer

AU - Kurland, Marge J.

AU - Sy, Lina S.

PY - 2007

Y1 - 2007

N2 - OBJECTIVE: To establish accurate, up-to-date, baseline epidemiological data for herpes zoster (HZ) before the introduction of the recently licensed HZ vaccine. METHODS: Using data from January 1, 1996, to October 15, 2005, we conducted a population-based study of adult residents (≥22 years) of Olmsted County, MN, to determine (by medical record review) the incidence of HZ and the rate of HZ-related complications. Incidence rates were determined by age and sex and adjusted to the US population. RESULTS: A total of 1669 adult residents with a confirmed diagnosis of HZ were identified between January 1, 1996, and December 31, 2001. Most (92%) of these patients were immunocompetent and 60% were women. When adjusted to the US adult population, the incidence of HZ was 3.6 per 1000 person-years (95% confidence interval, 3.4-3.7), with a temporal increase from 3.2 to 4.1 per 1000 person-years from 1996 to 2001. The incidence of HZ and the rate of HZ-associated complications increased with age, with 68% of cases occurring in those aged 50 years and older. Postherpetic neuralgia occurred in 18% of adult patients with HZ and in 33% of those aged 79 years and older. Overall, 10% of all patients with HZ experienced 1 or more nonpain complications. CONCLUSIONS: Our population-based data suggest that HZ primarily affects immunocompetent adults older than 50 years; 1 in 4 experiences some type of HZ-related complication.

AB - OBJECTIVE: To establish accurate, up-to-date, baseline epidemiological data for herpes zoster (HZ) before the introduction of the recently licensed HZ vaccine. METHODS: Using data from January 1, 1996, to October 15, 2005, we conducted a population-based study of adult residents (≥22 years) of Olmsted County, MN, to determine (by medical record review) the incidence of HZ and the rate of HZ-related complications. Incidence rates were determined by age and sex and adjusted to the US population. RESULTS: A total of 1669 adult residents with a confirmed diagnosis of HZ were identified between January 1, 1996, and December 31, 2001. Most (92%) of these patients were immunocompetent and 60% were women. When adjusted to the US adult population, the incidence of HZ was 3.6 per 1000 person-years (95% confidence interval, 3.4-3.7), with a temporal increase from 3.2 to 4.1 per 1000 person-years from 1996 to 2001. The incidence of HZ and the rate of HZ-associated complications increased with age, with 68% of cases occurring in those aged 50 years and older. Postherpetic neuralgia occurred in 18% of adult patients with HZ and in 33% of those aged 79 years and older. Overall, 10% of all patients with HZ experienced 1 or more nonpain complications. CONCLUSIONS: Our population-based data suggest that HZ primarily affects immunocompetent adults older than 50 years; 1 in 4 experiences some type of HZ-related complication.

UR - http://www.scopus.com/inward/record.url?scp=35848954757&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35848954757&partnerID=8YFLogxK

U2 - 10.4065/82.11.1341

DO - 10.4065/82.11.1341

M3 - Article

C2 - 17976353

AN - SCOPUS:35848954757

VL - 82

SP - 1341

EP - 1349

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 11

ER -